[Ip-health] TREAT Asia/amfAR, APN+ and ANPUD releases fact sheet on 2014 WHO hepatitis C guidelines.
giten.khwairakpam at treatasia.org
Wed Jul 2 04:09:53 PDT 2014
Hi George, Thanks for your feedback. Perhaps you have not understood the document and its contents- this is not what TREAT Asia/amfAR nor APN+ nor ANPUD is recommending.
What we have worked on is putting the key points from the recent WHO guidelines together so that people in the community finds it easy to understand what the guideline says.
If you think the treatment page is pretty much an antediluvian joke of horrible recommendations- then perhaps you should have flagged it when WHO launched their HCV guidelines in April this year. There is still time- you may write to WHO and tell them that what they have done is not upto the mark.
I am happy that the fact sheet is generating this feedback- which was missing when the actual guideline came out.
From: George Carter [mailto:fiar at verizon.net]
Sent: Wednesday, July 02, 2014 5:29 PM
To: Giten Khwairakpam
Cc: Ip-health at lists.keionline.org<mailto:Ip-health at lists.keionline.org>
Subject: Re: [Ip-health] TREAT Asia/amfAR, APN+ and ANPUD releases fact sheet on 2014 WHO hepatitis C guidelines.
Thanks Giten for sharing that but as a person living with hep C and who has friends in Asia living with it, this is depressing.
This document is depressing. While the first bits about assessing alcohol use and disease stage are common sense, the treatment page is pretty much an antediluvian joke of horrible treatment recommendations.
Of course, there is no mention of how micronutrient therapy and judicious use of botanicals can slow disease progression. However, we ALSO have CURES AVAILABLE. Sofosbuvir and daclatasvir can pretty much cure anyone, any genotype.
Why isn't AmFAR doing something actually useful like assessing the identity, potency and purity of generic sofosbuvir? Or are they so in the pocket of pharma that the best they'd offer is the second rate, ineffective (or at best marginally effective) horrifically toxic, long-term nightmare of PEG-IFN and ribavirin? And not to anyone who can't afford the drugs, let alone the syringes?
Whereas the new Directly Acting Antivirals (DAAs) can be made for maybe $400/patient (maybe less at a 4- or 8-week treatment period)?
So we get a nice pat, presentable, agreeable and useless regurgitation of crap that further delays and denies the possibility of discussing the public health issue of curing and eliminating a dangerous global pandemic in order to pander to greed in that typical obeisance to "realpolitik" garbage.
George M. Carter
On Jul 1, 2014, at 10:09 PM, Giten Khwairakpam wrote:
> Dear friends and colleagues,
> As a part of our efforts to increase awareness of and treatment access
> for hepatitis C and HIV co-infection, TREAT Asia/amfAR, the Asia
> Pacific Network of people living with HIV/AIDS (APN+) and the Asian
> Network of People who Use Drugs (ANPUD), are pleased to share a fact
> sheet based on the recent WHO Guidelines for the Screening, Care, and
> Treatment of Persons with Hepatitis C Infection, 2014
More information about the Ip-health